US lawmakers probe Merck, AbbVie over China clinical trials

A bipartisan group of US lawmakers has opened national security investigations into five major pharmaceutical companies—Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol-Myers Squibb (BMY)—over clinical trials conducted in China that may have supported the country's military capabilities, according to a report by Proactive.

Details of the Investigation

The investigation is led by bipartisan members of the House Foreign Affairs Committee and focuses on whether clinical trials conducted by these companies in China indirectly contributed to enhancing Chinese military capabilities. Investigators are demanding that the companies provide documents and information about clinical trials conducted in China over the past five years.

Company Responses

No official statements have been issued by all companies involved. However, some companies have confirmed they are fully cooperating with the investigation and comply with all applicable laws and regulations. They noted that clinical trials in China aim to develop new drugs for serious diseases and have no intention of supporting any military activities.

Precedents and Context

The investigations come amid rising tensions between the US and China over national security, trade, and technology issues. Washington has previously imposed restrictions on some Chinese companies, but this is the first time US pharmaceutical companies have been targeted for their activities in China.

Potential Financial Impact

The investigation could lead to fines or regulatory sanctions if violations are found, potentially negatively impacting the profits of the companies involved. It could also lead to changes in companies' strategies regarding clinical trials in China, potentially slowing the pace of new drug development.